\nSilence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the full year ended December 31, 2024, and provided a business update.<\/p>\n
\n\u201c2024 was marked by strong clinical execution and pipeline advancement, highlighting the broad potential of our mRNAi GOLD\u2122 platform to silence disease causing genes,\u201d said Craig Tooman, President and CEO of Silence. \u201cIn 2025, we are prioritizing investment in programs targeting rare conditions where we believe we can deliver on clear unmet needs with first-in-class and\/or best-in-class siRNAs. We believe divesiran is a great example of this strategy and clinical commitment. We are pleased to announce today that we anticipate full enrollment in the SANRECO Phase 2 study of divesiran in PV by year-end. While we remain confident in our zerlasiran program for high Lp(a), we will only initiate the Phase 3 cardiovascular outcomes study once a partner is secured.\u201d<\/p>\n
\n\u201cWe ended the year with over $147 million in cash, cash equivalents and short-term investments.\u201d said RhondaHellums, Chief Financial Officer at Silence. \u201cThe decision not to initiate the zerlasiran Phase 3 outcomes study without a partner extends our projected cash runway into 2027 and gives us flexibility to invest in our innovative pipeline while we continue partnering discussions for this program.\u201d<\/p>\n
Recent Business Highlights<\/b><\/p>\n
Zerlasiran for Cardiovascular Disease<\/b><\/p>\n Divesiran for Polycythemia Vera (PV)<\/b><\/p>\n Other mRNAi GOLD\u2122 Pipeline Updates<\/b><\/p>\n Financial Highlights for Year End 2024<\/b><\/p>\n 2025 Financial Guidance<\/b><\/p>\n Conference Call & Webcast Details<\/b><\/p>\n \nCompany management will host a conference call and webcast today, Thursday, February 27, 2025, at 8 a.m. EST \/ 1:00 p.m. GMT.<\/p>\n Webcast link: <\/b>https:\/\/edge.media-server.com\/mmc\/p\/73gzxc8m<\/b><\/a><\/p>\n Conference call registration link:<\/b>https:\/\/register.vevent.com\/register\/BIbb8ec3d3557e47e3a4db7b8c03339124<\/b><\/a><\/p>\n \nThe conference call and webcast will also be archived on the Company\u2019s website at www.silence-therapeutics.com<\/a>.<\/p>\n About Silence Therapeutics Forward-Looking Statements \n\u00a0<\/p>\n SILENCE THERAPEUTICS plc<\/b><\/p>\n CONSOLIDATED STATEMENTS OF INCOME (LOSS) <\/b><\/p>\n (in thousands, except for loss per share)<\/b><\/p>\n<\/td>\n<\/tr>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n Year ended December 31,<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n<\/tr>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n2024<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n2023<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2022<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nRevenue<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n43,258<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n31,643<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n21,655<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nCost of sales<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(11,810<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(12,867<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(13,463<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n Gross profit<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n 31,448<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n 18,776<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n 8,192<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n<\/tr>\n \nResearch and development costs<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(67,883<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(56,937<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(43,550<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nGeneral and administrative expenses<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(26,884<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(26,222<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(25,682<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n Operating loss<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n (63,319<\/b><\/p>\n<\/td>\n )<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n (64,383<\/b><\/p>\n<\/td>\n )<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n (61,040<\/b><\/p>\n<\/td>\n )<\/b><\/p>\n<\/td>\n<\/tr>\n \nForeign currency gain\/(loss), net<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n646<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(2,641<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,294<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nOther income, net<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n4,472<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,803<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n280<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nBenefit from R&D credit<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n13,737<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n11,949<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n9,820<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Loss before income tax expense<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n (44,464<\/b><\/p>\n<\/td>\n )<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n (53,272<\/b><\/p>\n<\/td>\n )<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n (49,646<\/b><\/p>\n<\/td>\n )<\/b><\/p>\n<\/td>\n<\/tr>\n \nIncome tax expense<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(845<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(956<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(688<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n Net Loss<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n $<\/b><\/p>\n<\/td>\n (45,309<\/b><\/p>\n<\/td>\n )<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n $<\/b><\/p>\n<\/td>\n (54,228<\/b><\/p>\n<\/td>\n )<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n $<\/b><\/p>\n<\/td>\n (50,334<\/b><\/p>\n<\/td>\n )<\/b><\/p>\n<\/td>\n<\/tr>\n Loss per share (basic and diluted)<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(0.33<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(0.49<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(0.52<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n Weighted average shares outstanding (basic and diluted)<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n138,752,224<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n111,277,250<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n96,584,512<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \n\u00a0<\/p>\n SILENCE THERAPEUTICS plc<\/b><\/p>\n CONSOLIDATED BALANCE SHEETS <\/b><\/p>\n (in thousands)<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n Year ended December 31,<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n<\/tr>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n2024<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n2023<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Current assets<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nCash and cash equivalents<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n121,330<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n68,789<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nShort-term investments<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n26,004<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nR&D benefit receivable<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n24,396<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n22,442<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nOther current assets<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n14,664<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n11,630<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nTrade receivables<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n972<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n290<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Total current assets<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n 187,366<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n 103,151<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n<\/tr>\n \nProperty, plant and equipment<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,818<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,938<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nOperating lease right-of-use assets<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n157<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n370<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nGoodwill<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n9,392<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n9,981<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nOther intangible assets<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n312<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n362<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nOther long-term assets<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3,590<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3,646<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Total assets<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n $<\/b><\/p>\n<\/td>\n 202,635<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n $<\/b><\/p>\n<\/td>\n 119,448<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n<\/tr>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Current liabilities<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nContract liabilities<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(306<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(6,571<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nTrade and other payables<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(16,399<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(15,537<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nOperating lease liabilities, current<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(117<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(228<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n Total current liabilities<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n (16,822<\/b><\/p>\n<\/td>\n )<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n (22,336<\/b><\/p>\n<\/td>\n )<\/b><\/p>\n<\/td>\n<\/tr>\n \nContract liabilities<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(51,790<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(75,001<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nOperating lease liabilities, long-term<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(118<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n Total liabilities<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n $<\/b><\/p>\n<\/td>\n (68,612<\/b><\/p>\n<\/td>\n )<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n $<\/b><\/p>\n<\/td>\n (97,455<\/b><\/p>\n<\/td>\n )<\/b><\/p>\n<\/td>\n<\/tr>\n \nCommitments and contingencies (Note 20)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Shareholders\u2019 equity<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nOrdinary shares – par value \u00a30.05 per share; 141,674,074 shares issued at December 31, 2024 (2023: 118,846,966)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(10,288<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(8,847<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nAdditional paid-in capital<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(609,560<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(455,765<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nAccumulated deficit<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n474,044<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n431,894<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nAccumulated other comprehensive loss<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n11,781<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n10,725<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Total shareholders’ equity<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n (134,023<\/b><\/p>\n<\/td>\n )<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n (21,993<\/b><\/p>\n<\/td>\n )<\/b><\/p>\n<\/td>\n<\/tr>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Total liabilities and shareholders’ equity<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n $<\/b><\/p>\n<\/td>\n (202,635<\/b><\/p>\n<\/td>\n )<\/b><\/p>\n<\/td>\n \u00a0<\/b><\/p>\n<\/td>\n $<\/b><\/p>\n<\/td>\n (119,448<\/b><\/p>\n<\/td>\n )<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n \n\u00a0<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250227003777\/en\/<\/a><\/span><\/p>\n Inquiries:<\/b><\/p>\n Silence Therapeutics plc KEYWORDS:<\/b> United Kingdom Europe<\/p>\n INDUSTRY KEYWORDS:<\/b> Health Clinical Trials Research Cardiology Science Biotechnology<\/p>\n\n
\n
\n
\n
\n
\n
<\/b>Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people\u2019s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD\u2122 platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit https:\/\/www.silence-therapeutics.com\/<\/a>.<\/p>\n
\n
<\/b>This press release contains \u201cforward-looking statements\u201d within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201ccould,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cforecasts,\u201d \u201cgoal,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cseeks,\u201d \u201cwill\u201d and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. All statements in this press release, other than statements of historical facts, are forward-looking statements. These statements include, but are not limited to, statements regarding: the Company\u2019s business strategy and plans, including its decision to prioritize the development of divesiran as the first-in-class siRNA product candidate for treatment of PV and programs in rare conditions with high unmet needs; the Company\u2019s clinical development activities and timelines for divesiran, including patient enrollment in the SANRECO Phase 2 trial; expected clinical benefits, efficacy and safety of divesiran and the potential to produce clinically meaningful outcomes in PV patients; the Company\u2019s plans to secure a partner to fund further clinical development of zerlasiran, including possible initiation of a Phase 3 clinical study; the design, timing, initiation, progress and results of current and future clinical development for the Company\u2019s other product candidates; and the Company\u2019s anticipated extended cash runway due to portfolio re-prioritization. Any forward-looking statements are based on management\u2019s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company\u2019s control. These risks and uncertainties include, but are not limited to: the impact of worsening macroeconomic conditions, including the conflict in Ukraine and the conflict between Israel and Hamas, heightened inflation and uncertain credit and financial markets, on the Company\u2019s business, clinical trials and financial position; the risk that success in preclinical testing and earlier clinical trials is not replicated in later clinical trials; the delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise; the Company\u2019s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; competition with respect to market opportunities; unexpected safety or efficacy data observed during preclinical studies or clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval; clinical trial site activation or enrollment rates that are lower than expected; the Company\u2019s ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. These and other risks and uncertainties are identified in the section titled “Risk Factors” in the Company\u2019s most recent Annual Report on Form 20-F for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d) on March 13, 2024 as updated by the section titled \u201cRisk Factors\u201d in the Company\u2019s Report on Form 6-K filed with the SEC on November 14, 2024, as well as its other documents subsequently filed with or furnished to the SEC. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.\u00a0<\/p>\n\n
\n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \u00a0<\/td>\n<\/tr>\n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/p>\n
\n<\/b>
Gem Hopkins, VP, Head of IR and Corporate Communications
\n
ir@silence-therapeutics.com
\n<\/a>
Tel: +1 (646) 637-3208<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20250227003777\/en\/2394424\/3\/Silence-Logo-FINAL-rgb.jpg\"){kind=logo}
<\/td>\n<\/tr>\n